ResVida® resveratrol exerts a positive effect on circulatory function in adults, study shows

Summary

This randomized, double-blind, placebo-controlled, cross-over trial was designed to evaluate the effects of resVida® resveratrol supplementation on both flow-mediated dilation (FMD) and cognitive performance in obese, but otherwise healthy, adults.

For this study, researchers followed 28 obese adults with an average BMI of 33.3+0.6 kg/m² who were randomly assigned to take either a single resVida® supplement (75 mg/day) or a placebo, each for a 6-week period. Blood pressure, arterial compliance, FMD, and cognitive performance on the Stroop Color-Word Test were assessed at the end of each 6-week intervention period while the participants were in a fasted state and at least 18 hours after taking the last daily capsule. An additional capsule of the same supplement was then taken followed by an FMD assessment 1 hour later.

The 6-week intervention with resVida® was well tolerated and resulted in a significant 23% increase in FMD compared to placebo (P=.02). The extent of the increase correlated negatively with baseline FMD (r=-0.47, P=.01). A single dose of resveratrol (75 mg) following chronic resveratrol supplementation for 6 weeks resulted in a 35% greater acute FMD response compared to placebo. These FMD improvements remained significant after adjusting for baseline FMD. Separately, resVida® supplementation had no significant effect on measures of blood pressure, arterial compliance or cognitive performance.

These findings suggest that a daily supplement of resVida® resveratrol (75 mg/day) is well tolerated and may help support healthy circulatory function in obese adults.